Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28133711 | 0.86 | HRH3 (0.50) | HRH3HRH4CYP3A4MAPTSMN1; SMN2 | |
| Pyridine SCHEMBL28192678 | 0.85 | HRH3 (0.49) | HRH3HRH4CYP3A4MAPTSMN1; SMN2 | |
| Pyridine SCHEMBL28265736 | 0.81 | HRH3 (0.38) | HRH3HRH4CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL1108477 | 0.80 | TAAR1 (0.50) | HRH3SMN1; SMN2TAAR1MAOA | |
| SCHEMBL8986293 | 0.79 | HRH3 (0.64) | HRH3HRH4TAAR1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL27287864 | 0.78 | TAAR1 (0.48) | HRH3CYP3A4MAPTSMN1; SMN2TAAR1 | |
| Pyridine SCHEMBL28868373 | 0.77 | HRH3 (0.54) | HRH3CYP11B1CYP11B2CYP19A1LOXL2 | |
| SCHEMBL79201 | 0.77 | MAOA (0.47) | MAOA | |
| SCHEMBL23528212 | 0.75 | DAO (0.44) | SMN1; SMN2TAAR1MAOA | |
| SCHEMBL11385118 | 0.75 | DAO (0.49) | MAPTSMN1; SMN2TAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS | 2022-01-27 | — | — | US | disclosed |
| US-10975030-B2 | Grp94 selective inhibitors and uses thereof | UNIVERSITY OF KANSAS (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975030-B2 | Grp94 selective inhibitors and uses thereof | UNIVERSITY OF KANSAS (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200071271-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2020-03-05 | — | — | US | disclosed |
| US-20200071271-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2020-03-05 | — | — | US | disclosed |
| WO-2018081814-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071271-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | GRPR, HSP90B1, HSPE1 | HRH3 2520/4885HRH4 1815/4885CYP3A4 3988/4885 |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | GRPR, HSP90B1, HSPE1 | HRH3 2520/4885HRH4 1815/4885CYP3A4 3988/4885 |
| US-10975030-B2 | Grp94 selective inhibitors and uses thereof | GRPR, HSP90B1, HSPE1 | HRH3 2520/4885HRH4 1815/4885CYP3A4 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.